| Allosteric activation of functionally asymmetric RAF kinase dimers J Hu, EC Stites, H Yu, EA Germino, HS Meharena, PJS Stork, AP Kornev, ... Cell 154 (5), 1036-1046, 2013 | 323 | 2013 |
| Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy S Kato, KH Kim, HJ Lim, A Boichard, M Nikanjam, E Weihe, DJ Kuo, ... Nature communications 11 (1), 4965, 2020 | 237 | 2020 |
| Network analysis of oncogenic Ras activation in cancer EC Stites, PC Trampont, Z Ma, KS Ravichandran Science 318 (5849), 463-467, 2007 | 149 | 2007 |
| Cancer gene mutation frequencies for the US population G Mendiratta, E Ke, M Aziz, D Liarakos, M Tong, EC Stites Nature communications 12 (1), 5961, 2021 | 138 | 2021 |
| Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing WS Liang, DW Craig, J Carpten, MJ Borad, MJ Demeure, GJ Weiss, T Izatt, ... Public Library of Science 7 (10), e43192, 2012 | 93 | 2012 |
| A systems mechanism for KRAS mutant allele–specific responses to targeted therapy T McFall, JK Diedrich, M Mengistu, SL Littlechild, KV Paskvan, ... Science signaling 12 (600), eaaw8288, 2019 | 59 | 2019 |
| A systems perspective of ras signaling in cancer EC Stites, KS Ravichandran Clinical Cancer Research 15 (5), 1510-1513, 2009 | 57 | 2009 |
| Tumour-immune dynamics with an immune checkpoint inhibitor E Nikolopoulou, LR Johnson, D Harris, JD Nagy, EC Stites, Y Kuang Letters in Biomathematics 5 (2), 137-159, 2018 | 51 | 2018 |
| Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling MS Creamer, EC Stites, M Aziz, JA Cahill, CW Tan, ME Berens, H Han, ... BMC systems biology 6, 1-14, 2012 | 49 | 2012 |
| Cooperation between noncanonical Ras network mutations EC Stites, PC Trampont, LB Haney, SF Walk, KS Ravichandran Cell reports 10 (3), 307-316, 2015 | 37 | 2015 |
| Sensitivity and versatility of an adaptive system for controlling cyclic movements using functional neuromuscular stimulation EC Stites, JJ Abbas IEEE transactions on biomedical engineering 47 (9), 1287-1292, 2000 | 37 | 2000 |
| The interpretation of SARS-CoV-2 diagnostic tests EC Stites, CB Wilen Med 1 (1), 78-89, 2020 | 34 | 2020 |
| Use of mechanistic models to integrate and analyze multiple proteomic datasets EC Stites, M Aziz, MS Creamer, DD Von Hoff, RG Posner, WS Hlavacek Biophysical journal 108 (7), 1819-1829, 2015 | 30 | 2015 |
| Innovations of the rule-based modeling approach LA Chylek, EC Stites, RG Posner, WS Hlavacek Systems Biology: integrative biology and simulation tools, 273-300, 2013 | 26 | 2013 |
| The response of cancers to BRAF inhibition underscores the importance of cancer systems biology EC Stites Science signaling 5 (246), pe46-pe46, 2012 | 24 | 2012 |
| Quantitative systems pharmacology analysis of KRAS G12C covalent inhibitors EC Stites, AS Shaw CPT: Pharmacometrics & Systems Pharmacology 7 (5), 342-351, 2018 | 20 | 2018 |
| Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach T McFall, EC Stites Cell reports 37 (11), 2021 | 19 | 2021 |
| KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery S Kato, T McFall, K Takahashi, K Bamel, S Ikeda, RN Eskander, S Plaxe, ... The oncologist 26 (4), e530-e536, 2021 | 16 | 2021 |
| Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors T McFall, NK Schomburg, KL Rossman, EC Stites Cell Communication and Signaling 18, 1-7, 2020 | 15 | 2020 |
| Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor KE Erickson, OS Rukhlenko, M Shahinuzzaman, KP Slavkova, YT Lin, ... PLoS computational biology 15 (1), e1006706, 2019 | 15 | 2019 |
